Page last updated: 2024-11-05

zaleplon and Depression, Involutional

zaleplon has been researched along with Depression, Involutional in 3 studies

zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam
zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.

Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.

Research Excerpts

ExcerptRelevanceReference
"Major depressive disorder is also highly comorbid in this population, leading to further impairment."5.62Treatment of Insomnia with Zaleplon in HIV+ Significantly Improves Sleep and Depression. ( Goldschmied, JR; Kayser, MS; Morales, KH; Sengupta, A; Sharma, A; Taylor, L; Thase, ME; Weljie, A, 2021)
"Major depressive disorder is also highly comorbid in this population, leading to further impairment."1.62Treatment of Insomnia with Zaleplon in HIV+ Significantly Improves Sleep and Depression. ( Goldschmied, JR; Kayser, MS; Morales, KH; Sengupta, A; Sharma, A; Taylor, L; Thase, ME; Weljie, A, 2021)
"Although it has been claimed that insomnia causes an increased risk for depression, adequate controlled trials testing this hypothesis have not been available."1.34Greater incidence of depression with hypnotic use than with placebo. ( Kripke, DF, 2007)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Goldschmied, JR1
Sengupta, A1
Sharma, A1
Taylor, L1
Morales, KH1
Thase, ME2
Weljie, A1
Kayser, MS1
Liskow, B1
Pikalov, A1
Kripke, DF1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A 6-week Open-Label Study of Treatment of Insomnia With Zaleplon in HIV Positive Patients With Comorbid Depression[NCT03489304]Phase 220 participants (Actual)Interventional2014-04-03Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Epworth Sleepiness Scale (ESS)

The Epworth Sleepiness Scale (ESS) is a validated sleep scale that quantifies daytime sleepiness across eight domains. The total score ranges from 0-24 where higher values indicate greater daytime sleepiness. (NCT03489304)
Timeframe: Measure at 6 weeks

Interventionscore on a scale (Mean)
Zaleplon6.5

Insomnia Severity Index (ISI)

The Insomnia Severity Index is a validated sleep scale that measures clinical insomnia severity. The total score ranges from 0-28 where higher values indicate increased severity of insomnia. (NCT03489304)
Timeframe: Measure at 6 weeks

Interventionscore on a scale (Mean)
Zaleplon11

Quick Inventory of Depressive Symptomatology (QIDS)

The Quick Inventory of Depressive Symptomatology (QIDS) is a validated mood scale that quantifies depression symptoms. The total score ranges from 0-48, where higher values indicate greater depressive symptoms. (NCT03489304)
Timeframe: Measure at 6 weeks

Interventionscore on a scale (Mean)
Zaleplon8.7

Other Studies

3 other studies available for zaleplon and Depression, Involutional

ArticleYear
Treatment of Insomnia with Zaleplon in HIV+ Significantly Improves Sleep and Depression.
    Psychopharmacology bulletin, 2021, 06-01, Volume: 51, Issue:3

    Topics: Acetamides; Depression; Depressive Disorder, Major; Humans; Pyrimidines; Quality of Life; Sleep; Sle

2021
Zaleplon overdose associated with sleepwalking and complex behavior.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2004, Volume: 43, Issue:8

    Topics: Acetamides; Adolescent; Child Behavior Disorders; Depressive Disorder, Major; Drug Overdose; Drug Th

2004
Greater incidence of depression with hypnotic use than with placebo.
    BMC psychiatry, 2007, Aug-21, Volume: 7

    Topics: Acetamides; Azabicyclo Compounds; Cross-Sectional Studies; Depressive Disorder, Major; Drug Prescrip

2007